You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

The Belgian ‘Cayman tax’ and its impact on wealth and estate planning in Belgium

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



Written resolutions of the board of directors

Written resolutions of the board of directors

Valérie Schrämli has recently published a short article about written resolutions in the board of directors of Swiss companies read more
Swiss Special Purpose Acquisition Company – Frequently Asked Questions

Swiss Special Purpose Acquisition Company – FAQ

The number of IPOs in the US more than doubled in 2020 compared to 2019. read more
Life Sciences Bit Tightened Swiss regulatory requirements in relation to international pharmaceuticals trading

Life Sciences Bit: Tightened Swiss regulatory requirements

Swiss wholesale license holder must tighten their audit practices towards suppliers from countries outside of the EU. read more